DERMATA THERAPEUTICS INC (DRMA) Stock Price, Forecast & Analysis
USA - NASDAQ:DRMA - US2498455045 - Common Stock
DRMA Key Statistics, Chart & Performance
The current stock price of DRMA is 2.56 USD. In the past month the price decreased by -37.71%. In the past year, price decreased by -77.49%.
DRMA Latest News, Press Relases and Analysis
DRMA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.45 | 408.15B | ||
| AMGN | AMGEN INC | 15.57 | 183.27B | ||
| GILD | GILEAD SCIENCES INC | 15.48 | 157.35B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.19 | 107.65B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.64 | 74.61B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 905.49 | 60.53B | ||
| INSM | INSMED INC | N/A | 42.73B | ||
| NTRA | NATERA INC | N/A | 29.87B | ||
| BIIB | BIOGEN INC | 9.97 | 24.47B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.05 | 21.55B | ||
| INCY | INCYTE CORP | 15.84 | 19.86B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 33.3 | 13.80B |
Related stock screener links
About DRMA
Company Profile
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2021-08-13. The firm is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.
Company Info
DERMATA THERAPEUTICS INC
3525 Del Mar Heights Rd., #322
San Diego CALIFORNIA US
CEO: Gerald T. Proehl
Employees: 8
Phone: 18582230882
DERMATA THERAPEUTICS INC / DRMA FAQ
What does DERMATA THERAPEUTICS INC do?
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2021-08-13. The firm is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.
What is the stock price of DERMATA THERAPEUTICS INC today?
The current stock price of DRMA is 2.56 USD. The price decreased by -4.12% in the last trading session.
What is the dividend status of DERMATA THERAPEUTICS INC?
DRMA does not pay a dividend.
What is the ChartMill rating of DERMATA THERAPEUTICS INC stock?
DRMA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting DRMA stock to perform?
7 analysts have analysed DRMA and the average price target is 10.2 USD. This implies a price increase of 298.44% is expected in the next year compared to the current price of 2.56.
What is the market capitalization of DRMA stock?
DERMATA THERAPEUTICS INC (DRMA) has a market capitalization of 1.74M USD. This makes DRMA a Nano Cap stock.
DRMA Technical Analysis
DRMA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DRMA. The financial health of DRMA is average, but there are quite some concerns on its profitability.
DRMA Financial Highlights
Over the last trailing twelve months DRMA reported a non-GAAP Earnings per Share(EPS) of -47.16. The EPS increased by 21.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -155.54% | ||
| ROE | -183.97% | ||
| Debt/Equity | 0 |
DRMA Forecast & Estimates
7 analysts have analysed DRMA and the average price target is 10.2 USD. This implies a price increase of 298.44% is expected in the next year compared to the current price of 2.56.